chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a medical assistant concerning a 13 month old male with no medical history and no known allergies who on the afternoon of 01/06/2003 was vaccinated in the left leg with a first dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (second generation) (lot #642702/0350M). There was no concomitant medication, and no illness at the time of vaccination. On 01/30/2003 (also reported as 01/28/2003) the pt developed a rash on his trunk and face. The physician reported  that this case was not just a rash but that it was "vaccinia - a measles like infection that occurs after vaccination accompanied by fever, malaise, rash and coryza." The physician said he had not seen this type of reaction in years and suspects that the vaccine might have been too virulent. The physician requested an investigation into that lot number performed. Unspecified medical attention was sought. The pt recovered on 01/30/2003. The records of testing prior to release of this lot have been checked by GMP Compliance and found to be satisfactory. The lot complies with the standard of the Center for Biologics Evaluation and Research was released. It was reported that two other patients received the same vaccine and also developed a measles like infection; (WAES #0302USA00198) and (WAES #0302USA00199). Additional info is not expected.
Pt recvd vax & devel abdo cramps, vomiting, diarrhea, flu-like sx; recovered by the next morning;
ASTHMA; This spontaneous report received from a patient concerned a male of unspecified age, race and ethnicity. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown, expiry: Unknown) dose, 1 total, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the patient experienced asthma, and was hospitalized (date unspecified). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of asthma was not reported. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0: 20210849243-Covid-19 vaccine ad26.cov2.s-Asthma. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Sedation, Myalgia, Arthralgia,  injection site tenderness, chills Narrative:  Note site tenderness evening of injection. Next day awoke with chills and developed myalgias/arthralgias as day progressed. Symptoms persisted into the next day. Also with significant fatigue and fitful sleep x 3 days. Missed work x 2.5 days. Prior mild COVID infection 10/01/2020.
About 10 mins after receiving both vaccines. She collapsed after feeling weak. BP was 95/60. No loss of consciousness, gradually recovered after another 5-10 minutes.
Discharge Diagnosis:  Hypoxia, COVID 19, Pulmonary HTN, ESRD, Type 2 MI, HTN.    Hospital Course:  The patient was admitted with the above. He was treated with 5 days of remdesevir and steroids. He was able to be weaned down to room air. He had not gotten dialysis for several months prior to being admitted so had to be set up for HD again outpatient. He was asked to follow up as an outpatient.
The client had a Hepatits B titer dram in May, 2023, but it was noted after the Hepatitis B vaccine was given that it was a Hepatits B surface ANTIGEN and not a Hepatitis B surface ANTIBODY titer. Thus, not a valid Hep B titer to determine antibodies and need for any further vaccine.
Minor reaction; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Minor reaction) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Minor reaction). At the time of the report, VACCINATION COMPLICATION (Minor reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant product use was reported  No treatment information was provided
I experienced moderate diarrhea approximately 3 days after receiving the second dose of my Pfizer-BioNTech vaccine.  I had no other symptoms  - no upset stomach, nausea, etc.  I received my second dose at 1:30p.m. on 4/2, and the diarrhea started at 5:00p.m. on April 5.  It was essentially water, and I had about 4 watery bowel-movements that evening and one the next day.  Around 2:00p.m. on April 6 I had a bowel movement that was more solid in consistency, and by the next day I was having regular bowel movements.  I had a somewhat upset stomach on April 6, but up until that point I did not have any other symptoms.  I do not believe that this was caused by anything I ate.
big red spot 3 inches across/it's red; it's itchy; it is hard; little bit tender; A little bit puffy; This spontaneous case was reported by a patient and describes the occurrence of TENDERNESS (little bit tender), SWELLING (A little bit puffy), ERYTHEMA (big red spot 3 inches across/it's red), PRURITUS (it's itchy) and INDURATION (it is hard) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     Concomitant products included POTASSIUM, ACETYLSALICYLIC ACID (BABY ASPIRIN), BENAZEPRIL, PANTOPRAZOLE, ATENOLOL, FUROSEMIDE, HYDROXYZINE, ATORVASTATIN, TELMISARTAN and MAGNESIUM for an unknown indication.    On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Feb-2021, the patient experienced TENDERNESS (little bit tender) and SWELLING (A little bit puffy). On 17-Feb-2021, the patient experienced ERYTHEMA (big red spot 3 inches across/it's red), PRURITUS (it's itchy) and INDURATION (it is hard). The patient was treated with PARACETAMOL (TYLENOL EXTRA STRENGTH) ongoing since an unknown date at a dose of UNK dosage form. On 10-Feb-2021, TENDERNESS (little bit tender) and SWELLING (A little bit puffy) had resolved. At the time of the report, ERYTHEMA (big red spot 3 inches across/it's red), PRURITUS (it's itchy) and INDURATION (it is hard) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Since the Moderna vaccine, I have been having debilitating headaches  to which I had to visit the emergency room. I have NEVER  experienced headaches like this. I thought maybe it would be a short lived side effect. Unfortunately, I am now having to make an appt. with a Neurologist which I have never done before. I know this vaccine is suppose to help us battle COVID.. It is important to note: THE VACCINE IS NOT FOR EVERYONE. I feel a deep a sense of frustration and regret for getting this vaccine as now I have to deal with these ongoing health issues. Also, I recently tested NEGATIVE for Covid19 just to rule out that it might be that.
This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Felt like hives), VACCINATION SITE MASS (Lump), VACCINATION SITE PRURITUS (Itching in injection site), VACCINATION SITE PAIN (Arm sore/ little sore arm) and VACCINATION SITE ERYTHEMA (Redness in injection site) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013A214) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included PROBIOTICS NOS, VITAMIN D3, LINUM USITATISSIMUM SEED OIL (FLAX OIL) and LYSINE for an unknown indication.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (Redness in injection site). On 11-Mar-2021, the patient experienced URTICARIA (Felt like hives), VACCINATION SITE MASS (Lump) and VACCINATION SITE PRURITUS (Itching in injection site). On an unknown date, the patient experienced VACCINATION SITE PAIN (Arm sore/ little sore arm). On 04-Mar-2021, VACCINATION SITE ERYTHEMA (Redness in injection site) had resolved. At the time of the report, URTICARIA (Felt like hives), VACCINATION SITE MASS (Lump), VACCINATION SITE PRURITUS (Itching in injection site) and VACCINATION SITE PAIN (Arm sore/ little sore arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       On 11-Mar-2021, the patient again had little sore arm.  No treatment information was provided.
Patient complained about not being able to move her arm. Pt refused for us to contact primary MD. .
Booster; COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 3 (booster), single, (Batch/Lot number: unknown) as dose 2, single and (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: IMMUNISATION (medically significant), outcome "unknown", described as "Booster"; DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19". Clinical course: The patient had both vaccines and the booster, all Pfizer, and stated, "why am I in the country with COVID being treated like a 2nd class citizen I will not promote your vaccine any longer. I have been a study voice for your product".  The lot number for bnt162b2 was not provided and will be requested during follow up.
Received Tdap on 9/19/07. Had already received on 11/1/05 but overlooked on faxed immunization records.
18 year old patient received PROQUAD as her first dose instead of receiving MMR and VZV separately.
I had body aches and chills; I had body aches and chills; A massive migraine which caused nausea when any movements were made; A massive migraine which caused nausea when any movements were made; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 26Apr2021 at 16:45 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included metoprolol (MANUFACTURER UNKNOWN) and ibuprofen (MANUFACTURER UNKNOWN); both from an unknown date for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 05Apr2021 at 17:15 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. The patient previously took amoxicillin; clavulanic acid (AUGMENTIN) for unknown indication and experienced drug allergy. On 27Apr2021 at 06:00, the patient had body aches and chills, a massive migraine which caused nausea when any movements were made. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events he had body aches and chills and a massive migraine which caused nausea when any movements were made was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Patient called 08/18/23 complaining of hair loss that started approximately 2 days after vaccination on 08/03/23.  There has been no treatment at this time.  She has an appointment soon with PCP.
I had a severe allergic reaction. The next morning, I woke up and my tongue, lips and the rest of my face was swollen and puffy. I also had tingling in my left hand and arm. I received the vaccine in my left arm, so I wonder if it's correlated. I went to my doctor and was advised to take Benadryl and Zyrtec for 3 days. Periodically, I still have tingling from my face, arms and hands. My left side has been most effected. And I feel fatigued and achy during these times.
8 days after injection, sore arm, swelling redness over large section of upper arm, itiching  and still present at day 15 after vaccination  chills, muscle ache fatigue at day 5 after injection and lasting 4 days
PATIENT LIED ABOUT DATE OF BIRTH ON COVID-19 REGISTRATION FORM . PATIENT WAS NOT ELIGIBLE FOR VACCINATION.
Information has been received from a physician concerning a 24 year old female patient who on 01/10/2003 was vaccinated with a dose of rubella virus vaccine live.  On 01/24/2003, two weeks after the vaccination, the patient developed a flat, papular rash.  It was unknown if medical attention was sought.  No further information was requested.
Redness, swelling at upper right arm that developed 2 days following injection. Went to ER on 12-17-12 - cellulitis diagnosed & given LEVAQUIN & clindamycin in the ER with a course of 6 day 5 of more clindamycin ordered.
Developed a fever between 102-104F; sore arms; injection site that was hot to the touch; This is a spontaneous report from a contactable nurse received via a Pfizer sales representative. This nurse reported similar events for three adolescent patients between the ages of 16-18. This is the 1st of three reports.   A patient of an unspecified gender received meningococcal group b rlp2086 (TRUMENBA), via an unspecified route of administration in the arm on an unspecified date at a single dose for immunization. The patient's medical history was not reported. Concomitant vaccine included meningococcal vaccine (MCV-4) on unspecified date for immunization. On an unspecified date, after use of the product, the patient developed a fever between 102-104F along with sore arms and an injection site that was hot to the touch. Injections were given in separate arms. Outcome of the events was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2019306418 same drug/event, different patient;US-PFIZER INC-2019306417 same drug/event, different patient
From provider's note: Patient is a 59yr old female who presents with concerns for left sided facial numbness. Received first dose of Moderna vaccine yesterday, within 30 minutes of administration patient began having numbness to the left side of her face. No issues with breathing or swallowing. Describes as similar to receiving Novocaine at the dentist. It has not worsened or improved over night. Has a history of GBS over 30 years ago. Has not received flu shot because of this. No contraindications to receiving SARS vaccine. No unilateral weakness. No headaches. She does have some discomfort over her injections site, she did receive the injection in her left arm.    Physical Exam: BP 134/97  Pulse 100  Temp 99.2 °F (37.3 °C) (Temporal)  Resp 16  Wt 79.4 kg (175 lb)  SpO2 98%  BMI 28.25 kg/m2|| Physical Exam  Constitutional: She is oriented to person, place, and time and well-developed, well-nourished, and in no distress.  Cardiovascular: Normal rate, regular rhythm and normal heart sounds.  No murmur heard. Pulmonary/Chest: Effort normal and breath sounds normal. No respiratory distress.  Neurological: She is alert and oriented to person, place, and time. She has normal motor skills, normal strength and intact cranial nerves. She displays normal speech. A sensory deficit is present. Gait normal.  **No facial droop, decreased sensation from midline of face along the left side to approximately ear ** Skin: Skin is warm and dry.   Plan: with the almost immediate presentation it is unlikely that vaccine caused reaction, but VAERS report to be completed. Will not burst with steroids as there does not appear to be facial nerve involvement. Patient is hypertensive today, when reviewing chart she has had a few episodes of hypertension over last visits. Will start on losartan, she had a BMP drawn in October. She is to follow up with a blood pressure check. Discussed red flag signs and symptoms of needing to return. Patient verbalized understanding and agreed with plan of care. Call or return to clinic as needed if these symptoms worsen or fail to improve as anticipated.
Expected her arm to hurt/Underarm started to hurt/Underarm started to hurt; Arm was really itchy/Had to scratch her arm; It was bizarre; Gland under her armpit into are breast tissue was swollen/Gland under her armpit into are breast tissue still tender; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Expected her arm to hurt/Underarm started to hurt/Underarm started to hurt), PRURITUS (Arm was really itchy/Had to scratch her arm), FEELING ABNORMAL (It was bizarre) and LYMPHADENOPATHY (Gland under her armpit into are breast tissue was swollen/Gland under her armpit into are breast tissue still tender) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032F21A, 010M20A and 002A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Nov-2021, the patient experienced PAIN IN EXTREMITY (Expected her arm to hurt/Underarm started to hurt/Underarm started to hurt), PRURITUS (Arm was really itchy/Had to scratch her arm), FEELING ABNORMAL (It was bizarre) and LYMPHADENOPATHY (Gland under her armpit into are breast tissue was swollen/Gland under her armpit into are breast tissue still tender). At the time of the report, PAIN IN EXTREMITY (Expected her arm to hurt/Underarm started to hurt/Underarm started to hurt), PRURITUS (Arm was really itchy/Had to scratch her arm), FEELING ABNORMAL (It was bizarre) and LYMPHADENOPATHY (Gland under her armpit into are breast tissue was swollen/Gland under her armpit into are breast tissue still tender) was resolving.            No concomitant medications were reported. No treatment information were reported. She stated he had clarified the information about the arm pain under the arm. Caller verified it was the left arm.   Most recent FOLLOW-UP information incorporated above includes: On 03-Nov-2021: Non-significant Follow Up Appended on 03 -Nov-21, included anatomical location and narrative updated.
pt taken to ER & stated that in evening pt was fussy & had twitching of the extremities; the twitching occurred while the pt was awake & not crying; no sz activity noted while in ER t99.9;
Lightheadedness, paleness, light fluctuates in vision field.  Provided patient with lollipop, animal crackers, and water.  Patient recovered within seconds.  Patient had not eaten any breakfast.
Received the 2nd dose <21 days; This spontaneous case was reported by a physician and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received the 2nd dose <21 days) in a 46-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 018B21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 on 23-Jun-2020.    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received the 2nd dose <21 days). On 21-Apr-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received the 2nd dose <21 days) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitants were reported. No treatment was reported.   Most recent FOLLOW-UP information incorporated above includes: On 26-May-2021: Non significant Follow up received on 26-may-2021.
Systemic: Confusion-Severe, Systemic: Dizziness / Lightheadness-Severe, Systemic: Fainting / Unresponsive-Severe, Additional Details: Patient fainted and was unresponsive for approximatly 5 minutes. EMT was called and checked out fine.
Approx 10 min after receiving flu vaccine Pt states :I feel funny. light headed and hot." Within seconds pt was nonverbal, eyes were open rolled to R side. Arms were contracted and pt was twitching. Lasted approx 60 sec. Pt was then alert and oriented x 3, but drowsy (slightly). Pt refused hospital visit. Pt to visit PMD. Vital signs stable. Blood sugar WNL/
Administrative deviation only; no adverse event resulted from this deviation. This patient received a mixed series of COVID-19 vaccine (one dose of Moderna and one dose of Pfizer-box #4 reflects the date of second dose). The decision to administer a mixed series to the patient was due to an "exceptional circumstance" stemming from the unavailability of the first vaccine product (Moderna) at the time the second dose was due. We understand that although CDC provides considerations for a mixed series in exceptional circumstances (such as a vaccine shortage, which was the case here), a mixed series is still considered an administration deviation that requires VAERS reporting. Note second vaccination date is listed.
Myalgia fatigue Narrative: Per nursing report: Took 2nd vaccine on 9-8-2. C/O aching and tired from vaccine., Did not come work on Sept. 9 and 10th due to vaccine side effects."